Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Stock Information for SES AI Corporation Class A

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About SES AI Corporation Class A

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Lexaria Bioscience Corp. Provides Strategic Update
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.